|
[1]
|
Torre, L.A., Siegel, R.L., Ward, E.M. and Jemal, A. (2016) Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiology, Biomarkers & Prevention, 25, 16-27. [Google Scholar] [CrossRef]
|
|
[2]
|
Etemadi, A., Safiri, S., Sepanlou, S.G., et al. (2020) The Global, Regional, and National Burden of Stomach Cancer in 195 Countries, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 5, 42-54.
|
|
[3]
|
Etemadi, A., Safiri, S., Sepanlou, S.G., et al. (2020) The Global, Regional, and National Burden of Stomach Cancer in 195 Countries, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 5, 42-54. [Google Scholar] [CrossRef]
|
|
[4]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Can-cers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
World Health Organization, International Agency for Research on Cancer (2020) GLOBOCAN 2020: Stomach Cancer Fact Sheet.
|
|
[6]
|
留成, 陈建思, 覃宇周, 黄名威, 金钦文. 进展期胃癌新辅助治疗病理完全缓解的研究进展[J]. 中国癌症防治杂志, 2021, 13(5): 559-564.
|
|
[7]
|
Cunningham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine, 355, 11-20. [Google Scholar] [CrossRef]
|
|
[8]
|
Batran, S.E., Homann, N., Pauligk, C., et al. (2019) Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. The Lancet, 393, 1948-1957. [Google Scholar] [CrossRef]
|
|
[9]
|
Tsuburaya, A., et al. (2014) Neoadjuvant Chemotherapy with S-1 and Cisplatin Followed by D2 Gastrectomy with Para-Aortic Lymph Node Dissection for Gastric Cancer with Ex-tensive Lymph Node Metastasis. British Journal of Surgery, 101, 653-660. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Hang, X.T., Liang, H., Li, Z.Y., et al. (2021) Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Patients with Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy (RESOLVE): An Open-Label, Superior-ity and Non-Inferiority, Phase 3 Randomised Controlled Trial. The Lancet Oncology, 22, 1081-1092. [Google Scholar] [CrossRef]
|
|
[11]
|
Xie, T.Y., et al. (2020) Early Results of the Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Chinese Advanced Gastric Cancer Patients (RESONANCE Trial). Journal of Clinical Oncology, 38, 280. [Google Scholar] [CrossRef]
|
|
[12]
|
Fukagawa, T., Katai, H., Mizusawa, J., et al. (2018) A Prospective Multi-Institutional Validity Study to Evaluate the Accuracy of Clinical Diagnosis of Pathological Stage III Gastric Cancer (JCOG1302A). Gastric Cancer, 21, 68-73. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Stahl, M., Walz, M.K., Riera-Knorrenschild J., et al. (2017) Pre-operative Chemotherapy versus Chemoradiotherapy in Locally Advanced Adenocarcinomas of the Oesophagogastric Junction (POET): Long-Term Results of a Controlled Randomised Trial. European Journal of Cancer, 81, 183-190. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Ajani, J.A., Winter, K., Okawara, G.S., et al. (2006) Phase II Trial of Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response. Journal of Clinical Oncology, 24, 3953-3958. [Google Scholar] [CrossRef]
|
|
[15]
|
Hofheinz, R.D., Haag, G.M., Ettrich, T.J., et al. (2020) Periopera-tive Trastuzumab and Pertuzumab in Combination with FLOT versus FLOT Alone for HER2-Positive Resectable Esophagogastric Adenocarcinoma: Final Results of the PETRARCA Multicenter Randomized Phase II Trial of the AIO. Journal of Clinical Oncology, 38, 4502. [Google Scholar] [CrossRef]
|
|
[16]
|
Zheng, Y.N., Yang, X., Yan, C., et al. (2020) Effect of Apatinib plus Neoadjuvant Chemotherapy Followed by Resection on Pathologic Response in Patients with Locally Ad-vanced Gastric Adenocarcinoma: A Single-Arm, Open-Label, Phase II Trial. European Journal of Cancer, 130, 12-19. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Japanese Gastric Cancer Association (2021) Japanese Gastric Can-cer Treatment Guidelines 2018 (5th Edition). Gastric Cancer, 24, 1-21. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Kaminishi, M., Yamaguchi, H., Shimizu, N., et al. (1997) Stom-ach-Partitioning Gastrojejunostomy for Unresectable Gastric Carcinoma. The Archives of Surgery, 132, 184-187. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Fujitani K., Yang, H.K., Mizusawa, J., et al. (2016) Gastrectomy plus Chemotherapy versus Hemotherapy Alone for Advanced Gastric Cancer with a Single Non-Curable Factor (REGATTA): A Phase 3, Randomised Controlled Trial. The Lancet Oncology, 17, 309-318. [Google Scholar] [CrossRef]
|
|
[20]
|
Shen, J., Ma, X., Yang, J., et al. (2020) Digestive Tract Re-construction Options after Laparoscopic Gastrectomy for Gastric Cancer. World Journal of Gastrointestinal Oncology, 12, 21-36. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
陈起跃, 钟情, 刘治羽, 黄晓波, 阙思瑾, 郑文泽, 李平, 郑朝辉, 黄昌明. 腹腔镜进展期胃癌根治术在中国的进展[J]. 中国肿瘤临床, 2021, 48(3): 110-117.
|
|
[22]
|
Moertel, C., Reitemeier, R., Childs, D., Colby, M. and Holbrook, M. (1969) Combined 5-Fluorouracil and Supervoltage Radiation Therapy of Locally Unresectable Gastrointestinal Cancer. The Lancet, 294, 865-867. [Google Scholar] [CrossRef]
|
|
[23]
|
Gastrointestinal Tumor Study Group (1982) A Comparison of Combination Chemotherapy and Combined Modality Therapy for Locally Advanced Gastric Carcinoma. Cancer, 49, 1771-1777.
http://www.ncbi.nlm.nih.gov/pubmed/6176313 [Google Scholar] [CrossRef]
|
|
[24]
|
Macdonald, J.S., Smalley, S.R., Benedetti, J., Hundahl, S.A., Estes, N.C., Stemmermann, G.N., et al. (2001) Chemoradiotherapy af-ter Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. The New England Journal of Medicine, 345, 725-730. [Google Scholar] [CrossRef]
|
|
[25]
|
Bang, Y.J., Kim, Y.W., Yang, H.K., et al. (2012) Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled Trial. The Lancet, 379, 315-321. [Google Scholar] [CrossRef]
|
|
[26]
|
Smalley, S.R., Benedetti, J.K., Haller, D.G., Hundahl, S.A., Estes, N.C., Ajani, J.A., et al. (2012) Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy versus Observation after Curative Gastric Cancer Resection. Journal of Clinical Oncology, 30, 2327-2333. [Google Scholar] [CrossRef]
|
|
[27]
|
Sasako, M., Sakuramoto, S., Katai, H., et al. (2011) Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy with S-1 versus Surgery Alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 29, 4387-4293. [Google Scholar] [CrossRef]
|
|
[28]
|
Yoshida, K., Kodera, Y., Kochi, M., et al. (2019) Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients with Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. Journal of Clinical Oncology, 37, 1296-1304. [Google Scholar] [CrossRef]
|
|
[29]
|
(2019) Interim Results of a Phase III Trial Involving Adjuvant Chemo-therapy and/or Chemoradiotherapy after D2-Gastrectomy in Stage II/III Gastric Cancer (GC). ASCO Annual Meeting, Chicago, 31 May-4 June 2019, Abstract 4001. [Google Scholar] [CrossRef]
|
|
[30]
|
Macedo, F., Ladeira, K., Longatto-Filho, A., et al. (2017) Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to As-sess Progression and Remission? Journal of Gastric Cancer, 17, 1-10. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Mawalla, B., Yuan, X., Luo, X., et al. (2018) Treatment Outcome of Anti-Angiogenesis through VEGF-Pathway in the Management of Gastric Cancer: A Systematic Review of Phase II and III Clinical Trials. BMC Research Notes, 11, 21-22. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Chuman, M., Takahashi, Y., Tokito, T., et al. (2019) A Case of Recurrent Gastric Cancer with Clinical Complete Response after Ramucirumab plus Paclitaxel Therapy. Gan to Kagaku Ryoho, 46, 1931-1933.
|
|
[33]
|
Kawai, S., Fukuda, N., Yamamoto, S., et al. (2020) Retrospective Observational Study of Salvage Line Ramucirumab Monotherapy for Patients with Ad-vanced Gastric Cancer. BMC Cancer, 20, 338-340. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Jang, J., Kim, H.K., Bang, H., et al. (2017) Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. Translation-al Oncology, 10, 469-475. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Li, J., Qin, S., Xu, J., et al. (2016) Randomized, Double-Blind, Placebocontrolled Phase III Trial of Apatinib in Patients with Chemotherapy Refractory Advanced or Metastatic Adeno-carcinoma of the Stomach or Gastroesophageal Junction. Journal of Clinical Oncology, 34, 1448-1454. [Google Scholar] [CrossRef]
|
|
[36]
|
Aguilar-Mahecha, A., Joseph, S., Cavallone, L., et al. (2019) Pre-cision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report. Frontiers in Oncology, 9, 698-699. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Muro, K., Chung, H., Shankaran, V., et al. (2016) Pembrolizumab for Patients with PD-L1-Positive Advanced Gastric Cancer (KEYNOTE-012): A Multicentre, Open-Label, Phase 1b Tri-al. The Lancet Oncology, 17, 717-726. [Google Scholar] [CrossRef]
|
|
[38]
|
Fuchs, C.S., Doi, T., Jang, R.W., et al. (2018) Safety and Ef-ficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncology, 4, e180013. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Kang, Y.-K., Boku, N., Satoh, T., et al. (2017) Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Pre-vious Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 390, 2461-2471. [Google Scholar] [CrossRef]
|
|
[40]
|
Moehler, M., Dvorkin, M., Boku, N., et al. (2021) Phase III Trial of Avelumab Maintenance after First-Line Induction Chemotherapy versus Continuation of Chemotherapy in Pa-tients with Gastric Cancers: Results from JAVELIN Gastric 100. Journal of Clinical Oncology, 39, 966-977. [Google Scholar] [CrossRef]
|
|
[41]
|
Boku, N., Satoh, T., Ryu, M., Chao, Y., et al. (2021) Nivolumab in Previously Treated Advanced Gastric Cancer (ATTRACTION-2): 3-Year Update and Outcome of Treatment beyond Progression with Nivolumab. Gastric Cancer, 24, 946-958. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Peng, Z., Wei, J., Wang, F., et al. (2021) Camrelizumab Com-bined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-Line Therapy for Advanced Gastric or Gas-troesophageal Junction Adenocarcinoma. Clinical Cancer Research, 27, 3069-3078. [Google Scholar] [CrossRef]
|
|
[43]
|
Wang, F., Wei, X.L., Wang, F.H., et al. (2019) Safety, Ef-ficacy and Tumor Mutational Burden as a Biomarker of Overall Survival Benefit in Chemo-Refractory Gastric Cancer Treated with Toripalimab, a PD-1 Antibody in Phase Ib/II Clinical Trial NCT02915432. Annals of Oncology, 30, 1479-1486.
|
|
[44]
|
Jiang, H., Zheng, Y., Qian, J., et al. (2020) Safety and Efficacy of Sintilimab Combined with Oxali-platin/Capecitabine as First-Line Treatment in Patients with Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in a Phase Ib Clinical Trial. BMC Cancer, 20, 760. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
U.S. Food and Drug Administration. (2021) FDA Grants Accel-erated Approval to Dostarlimab-Gxly for dMMR Advanced Solid Tumors.
https://www.fda.gov/drugs/resourcesinformation-approved-drugs/fda-grants-accelerated-approvaldostarlimab-gxly-dmmr-advanced-solid-tumors
|